Stock ABUS ARBUTUS BIOPHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq
Other stock markets
 04:00:02 2024-04-23 pm EDT 		5-day change 1st Jan Change
2.74 USD +3.79% Intraday chart for Arbutus Biopharma Corporation -6.16% +9.60%
Apr. 05 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
Apr. 04 Moderna Suffers Setback in Lawsuit by Arbutus MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
GL
Arbutus Biopharma : Corporate Presentation - April 2024
PU
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit
MT
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
GL
Moderna Suffers Setback in Lawsuit by Arbutus
MT
Moderna shares fall after judge sides with Arbutus in patent fight
RE
Transcript : Arbutus Biopharma Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM
Arbutus to Participate in Two Upcoming Investor Conferences
GL
Arbutus to Participate in Two Upcoming Investor Conferences
AQ
HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating
MT
Arbutus Biopharma Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
AQ
Transcript : Arbutus Biopharma Corporation, Q4 2023 Earnings Call, Feb 29, 2024
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
GL
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
AQ
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
GL
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
GL
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
AQ
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline
CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABUS Stock
  4. News Arbutus Biopharma Corporation